Journal
CELL
Volume 185, Issue 7, Pages 1189-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2022.02.021
Keywords
-
Categories
Funding
- SiRIC-Curie Program [INCa-DGOS-12554]
- Labex DCBIOL [ANR-10-IDEX-0001-02 PSL, ANR-11-LABX-0043]
- Fondation ARC [PA20181207706]
- Ligue Nationale contre le cancer [RS19/75-92]
- Center of Clinical Investigation (CIC IGR-Curie) [1428]
- ITMO-CancerAviesan (Plan Cancer III) [ANR-10-EQPX-03, ANR-10-INBS-09-08]
- SiRIC-Curie program (SiRIC Grant) [INCa-DGOS-4654]
- NIHR Manchester BRC
- Cancer Research UK Manchester Institute Award [A19258]
- IDEX [ANR-18-IDEX-0001]
- INCA [PL-BIO-ICR1]
- [IG23179]
- [ANR-17-CE11-0001-01]
Ask authors/readers for more resources
This study identifies a specific population of FOLR2(+) tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors, which interact with CD8(+) T cells and positively correlate with better patient survival.
Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2(+) tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors. FOLR2(+) macrophages localize in perivascular areas in the tumor stroma, where they interact with CD8(+) T cells. FOLR2(+) macrophages efficiently prime effector CD8(+) T cells ex vivo. The density of FOLR2(+) macrophages in tumors positively correlates with better patient survival. This study highlights specific roles for tumor-associated macrophage subsets and paves the way for subset-targeted therapeutic interventions in macrophages-based cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available